Botulinum toxin therapy, immunologic resistance, and problems with available materials

Neurology

Volumn 46, Issue 1, 1996, Pages 26-29

  Borodic, Gary ^a,c   Johnson, Eric ^b   Goodnough, Mike ^b   Schantz, Edward ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN F; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

BIOASSAY; BLEPHAROSPASM; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; LD 50; MOTOR DYSFUNCTION; PRIORITY JOURNAL; REVIEW; SPASMODIC TORTICOLLIS;

EID: 0029977787     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.1.26     Document Type: Review

References (20)

1. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology (in press).
2. Schantz E. Historic perspectives. In Jantovic J, and Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994.
3. Johnson E, Goodnough M. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Micrbiol 1992;58: 3426-3428.
4. Borodic GE, Pearce LB, Johnson E. Antibodies to botulinum toxin. Ophthalmology 1994;101:1158-1159.
5. Hambleton P, Cohen HE, Palmer BJ, Melling J. Antitoxins and botulinum toxin treatment. BMJ 1992;304:959-960.
6. Jankovic J, Schwartz K. Clinical correlates of response to botulinum toxin injections. Arch Neurol 1991;48:1253-1256.
7. Green P, Fahn S. Use of botulinum type F injections to treat torticollis in patients with immunity to type A. Mov Disord 1993;8:479-483.
8. Pearce LB, Borodic GE, First ER, MacCallum RD. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994;128:69-77.
9. First E, Pearce LB, Borodic GE. Dose standardization with botulinum toxin for human use. Lancet 1994;343:1035.
10. Borodic GE, Johnson E, Goodnough M. Myogenic ptosis model for evaluation of botulinum toxin activity. Ophthal Plast Reconstr Surg (in press).
11. Pearce LB, Borodic GE, Johnson EA, First ER, MacCallum R. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon 1995;33: 217-227.
12. Biglan AW, Gonnering R, Lockhart LB, Rabin B, Fuerste FH. Absence of antibody production in patients treated with botulinum A toxin. Am J Ophthalmol 1986;101:232-235.
13. Gonnering RS. Negative antibody response to long-term treatment of facial spasms with botulinum toxin. Am J Ophthalmol 1988;105:313-315.
14. Hathaway C, Dang C. Immunogenicity of the neurotoxin of clostridium botulinum. In Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994.
15. Tsui JK, Wong NLM, Wong E, Calne DB. Production of circulating antibodies to botulinum-A toxin in patients receiving repeated injections for dystonia [abstract]. Ann Neurol 1988; 23:181.
16. Zuber M, Sebald M, Bathien N, et al. Botulinum antibodies in dystonic patients treated with type A botulinum toxin, frequency and significance. Neurology 1993;43:1715-1718.
17. Siatkowski RM, Tyutyunikow A, Biglan AW. Serum antibody production to botulinum A toxin. Ophthalmology 1993;100: 1861-1866.
18. Cardella MA. Botulinum toxoids. In Lewis KH, Cassel K Jr, eds. Botulism: proceedings of a symposium. Washington, DC: Government Printing Office 1964:113-130. [PHS Publ. No. 999-FRI.]
19. Borodic GE, Pearce B, Duane D, Johnson E. Antibodies to botulinum toxin [letter]. Neurology 1995;45:204.
20. Brin M, Blitzer A. Botulinum toxin, dangerous terminology errors. J R Soc Med 1993;86:493-494.